6,176
Views
10
CrossRef citations to date
0
Altmetric
Epidemiology

Incidence of amyotrophic lateral sclerosis in the United States, 2014–2016

, , , , , & show all
Pages 378-382 | Received 20 Oct 2021, Accepted 17 Dec 2021, Published online: 13 Jan 2022

References

  • Mitsumoto H. Amyotrophic Lateral Sclerosis. Philadelphia, PA: FA Davis Company; 1998: 480.
  • Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67:1285–9.
  • Mehta P, Raymond J, Punjani R, Larson T, Bove F, Kaye W, et al. Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016. Amyotroph Lateral Scler Frontotemporal Degener. 2021;0:1–6.
  • Massachusetts Department of Public Health. Massachusetts ALS Registry. Available at: https://www.mass.gov/als-registry.
  • Wagner L, Rechtman L, Jordan H, Ritsick M, Sanchez M, Sorenson E, et al. State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17:128–34.
  • Mehta P, Antao V, Kaye W, Sanchez M, Williamson D, Bryan L, Centers for Disease Control and Prevention (CDC), et al. Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011. MMWR Suppl. 2014;63:1–14.
  • Mehta P, Kaye W, Bryan L, Larson T, Copeland T, Wu J, et al. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2012-2013. MMWR Surveill Summ. 2016;65:1–12.
  • Mehta P, Kaye W, Raymond J, Wu R, Larson T, Punjani R, et al. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2014. MMWR Morb Mortal Wkly Rep. 2018;67:216–8.
  • Kaye WE, Sanchez M, Wu J. Feasibility of creating a National ALS Registry using administrative data in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:433–9.
  • Allen KD, Kasarskis EJ, Bedlack RS, Rozear MP, Morgenlander JC, Sabet A, et al. The National Registry of Veterans with amyotrophic lateral sclerosis. Neuroepidemiology 2008;30:180–90.
  • U.S. Census Bureau Population Division. Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States: April 1, 2010 to July 1, 2019 (NC-EST2019-AGESEX), Release date: June 2020.
  • U.S. Census Bureau Population Division. Annual Estimates of the Resident Population by Sex, Age, Race Alone or in Combination, and Hispanic Origin for the United States: April 1, 2010 to July 1, 2019 (NC-EST2019-ASR5H), Release Date: June 2020.
  • Punjani R, Wagner L, Horton K, Kaye W. Atlanta metropolitan area amyotrophic lateral sclerosis (ALS) surveillance: incidence and prevalence 2009-2011 and survival characteristics through 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:123–30.
  • Freer C, Hylton T, Jordan HM, Kaye WE, Singh S, Huang Y. Results of Florida's Amyotrophic Lateral Sclerosis Surveillance Project, 2009-2011. BMJ Open. 2015;5:e007359.
  • Henry KA, Fagliano J, Jordan HM, Rechtman L, Kaye WE. Geographic Variation of Amyotrophic Lateral Sclerosis Incidence in New Jersey, 2009-2011. Am J Epidemiol. 2015;182:512–9.
  • Jordan H, Fagliano J, Rechtman L, Lefkowitz D, Kaye W. Population-based surveillance of amyotrophic lateral sclerosis in New Jersey, 2009-2011. Neuroepidemiology 2014;43:49–56.
  • Rechtman L, Jordan H, Wagner L, Horton DK, Kaye W. Racial and ethnic differences among amyotrophic lateral sclerosis cases in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:65–71.
  • Valle J, Roberts E, Paulukonis S, Collins N, English P, Kaye W. Epidemiology and surveillance of amyotrophic lateral sclerosis in two large metropolitan areas in California. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:209–15.
  • Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41:118–30.
  • Miller C, Apple S, Paige JS, Grabowsky T, Shukla O, Agnese W, et al. Current and future projections of amyotrophic lateral sclerosis in the United States using administrative claims data. Neuroepidemiology. 2021;55:275–85.
  • Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32:771–6.
  • Richards D, Morren JA, Pioro EP. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J Neurol Sci. 2020;417:117054.
  • Hardiman O, Al-Chalabi A, Brayne C, Beghi E, van den Berg LH, Chio A, et al. The changing picture of amyotrophic lateral sclerosis: lessons from European registers. J Neurol Neurosurg Psychiatry. 2017;88:557–63.
  • Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–55.
  • Su FC, Goutman SA, Chernyak S, Mukherjee B, Callaghan BC, Batterman S, et al. Association of environmental toxins with amyotrophic lateral sclerosis. JAMA Neurol. 2016;73:803–11.
  • Bozzoni V, Pansarasa O, Diamanti L, Nosari G, Cereda C, Ceroni M. Amyotrophic lateral sclerosis and environmental factors. Funct Neurol. 2016;31:7–19.
  • McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med. 2010;7:557–70.
  • Census Reporter, Midwest Region, 2019. Available at: https://censusreporter.org/profiles/02000US2-midwest-region/.
  • Larson TC, Kaye W, Mehta P, Horton DK. Amyotrophic lateral sclerosis mortality in the United States, 2011-2014. Neuroepidemiology 2018;51:96–103.
  • Brookings Institution. A pre-2020 census look at the wide dispersal of the nation’s Hispanic, Asian and black populations, Available at https://www.brookings.edu/research/americas-racial-diversity-in-six-maps/2020.
  • Reichard A, McDermott S, Ruttenber M, Mann J, Smith MG, Royer J, et al. Testing the feasibility of a passive and active case ascertainment system for multiple rare conditions simultaneously: the experience in three US states. JMIR Public Health Surveill. 2016;2:e151.